ResMed (NYSE: RMD) reported Q4 EPS of $1.60, $0.07 worse than the analyst estimate of $1.67. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.14 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.